Lilly backs OrsoBio’s $60M Series A for PhII trials in obesity and NASH

OrsoBio, a biotech focused on obesity and metabolic disorders, is getting financial support from one of the leading drugmakers in the field as Eli Lilly helps back its $60 million Series A round.

OrsoBio, based in Menlo Park, CA, is an amalgamation of assets from Gilead, Shionogi, Phenex Pharmaceuticals and…
Click here to view original post